

precision medicine forum

11-12 July 2016, London



Speakers include:

George Freeman MP, UK Minister for Life Sciences, **Dept. of Health**

Dr David Roblin FRCP FFPM, Chief Operating Officer & Director of Scientific Translation, **The Francis Crick Institute**

Dr Menelas N Pangalos FMedSci, Executive Vice President, **AstraZeneca**

Sir John Chisholm Executive Chair, **Genomics England**

Prof. Sue Hill Chief Scientific Officer, **NHS England**

Dr Rowena Sharpe Head of Precision Medicine, **Cancer Research UK**

Dr Clare Turnbull Clinical Lead for 100K Genome Project Cancer Programme, **Genomics England**

Prof. Dr. med. Nisar Peter Malek Director Center for Personalized Medicine, **University of Tübingen** Managing Director Dept. of Internal Medicine, **University Hospital Tübingen**

Dr Mark A. Rubin Founding Director, Englander Institute for Precision Medicine, **Weill Cornell Medical College and New York-Presbyterian Hospital**

Dr Damian Smedley Director of Genomic Interpretation and Associate Director of Bioinformatics, **Genomics England**

Rolf Apweiler Director, **EMBL-EBI (European Bioinformatics Institute)**

Caroline Heckman PhD Group Leader and Principal Investigator, **FIMM**

Alistair Kent OBE Director, **Genetic Alliance UK**



Facilitating Global Collaboration

Through a combination of professionally facilitated panel discussions, focussed round table sessions, open networking sessions and "elevator pitch" style technology overviews **Precision Medicine Forum** London will allow you to really get to the crux of your challenges, share solutions and meet your peers, to provide an unrivalled learning and networking environment.

How to Register:

W: www.precisionmedicineforum.com/conferences

E: register@precisionmedicineforum.com

T: +44(0)1273 931616

Associate Sponsors



Exhibitors



www.precisionmedicineforum.com

Join us in London for our interactive forum

A new era of medicine is upon us, in which omics, science and technology are meeting to enable a sea change in the way healthcare is provided. But, if the ambitious goal of Precision Medicine is to be achieved, it requires the creative and energetic involvement of many, from biologists, physicians and technology developers to data scientists, patient groups, governments and more. Interest in the initiative's goals has motivated and attracted visionary scientists from many disciplines but, for these efforts to be truly successful, they must cover all corners of the globe and will require significant collaboration.

And that's where Precision Medicine Forum London comes in. We will get away from lengthy powerpoint presentations

allowing all attendees to participate in discussions in an intimate and focussed environment, meaning you truly gain from the collective wisdom of some of the world's leading scientific minds.

Meet with those at the forefront of the healthcare revolution. From NGS to CDx, health economics to Big Data, biomarker discovery to clinical trials, oncology to rare disease and research to the clinic.

We look forward to welcoming you to Precision Medicine Forum London and enabling real discussions about the future of healthcare.



Vivienne Parry OBE (Chair)

We are excited to be working with Vivienne who brings her inimitable style to Precision Medicine Forum London. A scientist by training, Vivienne hosts medical programmes for Radio 4, writes widely on health, presents films, facilitates many high level conferences and debates and trains young researchers. She also has a part time role as head of engagement at Genomics England which is delivering the 100,000 Genomes Project.



Day one 11 July 2016

8.00 Registration

9.10 Opening Remarks from The Chair:

Vivienne Parry OBE

9.15 Keynote Panel Session

George Freeman MP, UK Minister for Life Sciences, Dept. of Health

Sir John Chisholm, Executive Chair, Genomics England

Prof. Sue Hill, Chief Scientific Officer, NHS England

10.15 Recent Success Stories and The Future of Cancer

Dr Rowena Sharpe, Head of Precision Medicine, Cancer Research UK

Dr Clare Turnbull, Clinical Lead for 100K Genome Project Cancer Programme, Genomics England

11.00 Refreshments and Networking

11.30 Integrating Personal Genomics, Big Data and Bioinformatics:

The Challenges of a large scale genome project:

Dr Damian Smedley will give examples of some of the hurdles to overcome in the course of the 100K Genome project and lessons learned

Dr Damian Smedley, Director of Genomic Interpretation and Associate Director of Bioinformatics, Genomics England

From biobanks and big data to precision cancer medicine:

Caroline Heckman PhD's research is focused on understanding basic mechanisms of cancer pathogenesis and drug resistance using big data platforms such as high throughput screening and next generation genome sequencing, with results applied real time for patient care. The findings are also used to identify new treatment strategies, particularly for patients with recurrent disease, identify biomarkers for treatment response, and develop new methods for patient stratification.

Caroline Heckman PhD, Group Leader and Principal Investigator, Institute for Molecular Medicine Finland (FIMM)

Bioinformatics Goes Translational: Infrastructural Challenges and Opportunities:

Molecular biology is increasingly relevant to clinical research and, in some cases, practicing medicine. This is because the costs of automated data-gathering technologies – most notably DNA sequencing but also

proteomics and metabolomics – have dropped precipitously over the past decade and continue to fall. Coupled with cost-effective imaging techniques, a large amount of data can be gathered and integrated to help inform both clinical research and practicing medicine.

Rolf Apweiler, Director, EMBL-EBI
(European Bioinformatics Institute)

Julia Fan Li, Senior Vice President, Seven Bridges

12.45 Tom O'Leary, Chief Information Officer, ICON Plc

13.00 The Global View of Precision Medicine from the perspective of big pharma:

Dr Menelas N Pangalos FMedSci, Executive Vice President, AstraZeneca's Innovative Medicines and Early Development Biotech Unit

13.30 Networking Lunch

14.30 Round-table sessions:

Following extensive research and consultation with the key industry stakeholders we drill down to uncover what the major issues facing us in the implementation of Precision Medicine are. These issues form the basis of the round-table sessions. After an introduction by the moderator and brief introduction from each participant as to their role and responsibility, the session then continues with all participants fully engaged in the sharing of ideas, experiences, business process and opinion. The sessions will have 10-12 topics from which attendees can choose their preference.

Each moderator will present the main themes of the round table they chaired allowing the whole audience to get a feel for some of the key issues discussed around each topic

Choose from one of the following:

- Health Economics
- Rare Disease
- Oncology
- Next Generation Sequencing
- CTCs/Liquid Biopsy
- Building global, multi-discipline partnerships
- Clinical implementation of Precision Medicine
- Pharmacogenomics
- Big data and analytics
- Companion Diagnostics
- Biomarker
- Clinical Trials
- Proteomics

16.00 Refreshments and Networking

16.30 Building a Patient Cohort – Experiences of The Precision Medicine Initiative in the USA

Dr Mark A. Rubin, Founding Director, Englander Institute for Precision Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital

17.00 The Patients perspective

Hear from a panel of patients about their experiences of precision medicine. This session really brings the concept of precision medicine into reality.

Some of the areas covered will include:

- Data ownership
- How many biopsies are too many biopsies
- Public perception of Precision Medicine
- Dynamic consent

18.00 Networking Drinks reception

Day Two 12 July 2016

9.00 Opening remarks

9.05 Rare Disease and Patient Access:

The role of patients and families in shaping research - and the opportunities/potential for improving the design of clinical development programmes so they get to the point where they can both satisfy the Regulators of their quality, safety and efficacy and the HTA bodies of their clinical and cost effectiveness more quickly and effectively

Alastair Kent OBE, Director, Genetic Alliance UK

The UK compared to EU related to adoption of EMA approved orphan medicines

The historical framework for HTA assessment of orphan medicines in the UK

How does NICE HST and the Office for Market Access interact with industry

Case study of BioMarin and managed entry through NICE HST

Lessons learned and future trends.

Nigel Nicholls, Director and Country Manager UK/Ireland, BioMarin Europe Ltd

Sheela Upadhyaya, Associate Director – Highly Specialised Technologies, NICE

Edmund Jessop, Public Health Adviser

10.15 The Economics of Precision Medicine:

Rethinking Healthcare – The Need for a New System

The use of biomarkers in personalized medicine bears the potential to discover, develop and market new treatments that may significantly increase therapy effectiveness for serious diseases such as cancer or disorders of the central nervous system. However, if treatments are 'personalized', the targeted patient population shrinks. As a result, personalized treatments are introduced at premium prices in order to still create a profit for the developer or marketer. Extrapolating healthcare expenses by considering expected launches of new, biomarker-enabled personalized therapies shows that either healthcare budgets will need to grow substantially, or that costs of clinical

New speakers are being added daily.

Please check www.precisionmedicineforum.com for the latest programme

development and marketing have to go down significantly in order to create sustainable healthcare systems.

The contribution will discuss the following issues:

- premium product pricing and value to patients and drug developers,
- future healthcare budget requirements,
- potential approaches to make healthcare systems sustainable.

Joachim M. Greuel, Ph.D., MBA, Managing Director, Bioscience Valuation BSV GmbH

Prof Katherine Payne, Professor of Health Economics, The University of Manchester

11.15 Refreshments and Networking

11.45 The Critical Role of Biomarkers & Companion Diagnostics Development

Global Commercialization and Market Access for Companion Diagnostics

Iain D. Miller, Ph.D. Founder, Healthcare Strategies Group

Liquid Biopsy

The concept of liquid biopsy may provide an important milestone towards precision medicine in cancer therapy by enabling longitudinal treatment monitoring and providing actionable information for therapy selection. Circulating Tumor Cells (CTCs), circulating free tumor DNA (ctDNA) and circulating micro-RNAs (miRNAs) as blood-based biomarkers offer the possibility to detect driver mutations, emerging resistance and epigenetic changes in molecular pathomechanisms. However, the currently available technologies for enrichment, isolation and analysis of the markers lack harmonized protocols for pre-analytical sample handling and biobanking, analytical standards and defined workflows for downstream analysis. The Innovative Medicines Initiative consortium CANCER-ID addresses the issues in a public-private partnership reaching out to all relevant stakeholders.

Dr. Thomas Schlange, Senior Biomarker Scientist, Bayer and EFPIA coordinator Innovative Medicines Initiative (IMI) consortium CANCER-ID

Yiu-Lian Fong, Ph.D, MBA, Senior Director, Global Diagnostic Innovation, Johnson & Johnson

Professor Clive Morris, Chief Medical Officer, Inivata

13.00 Networking Lunch

14.00 At the cutting edge of Biomedical discovery

Dr David Roblin FRCP FFCM
Chief Operating Officer & Director of Scientific Translation
The Francis Crick Institute

14.30 Implementing Precision Medicine in the Clinic:

Prof. Dr. med. Nisar Peter Malek, Director Center for Personalized Medicine, University of Tübingen Managing Director Dept. of Internal Medicine, University Hospital Tübingen

Dr Mark A. Rubin, Founding Director, Englander Institute for Precision Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital

Mainstreaming genomics in the health system

Based on long experience of working with different clinical specialties to develop national guidance and policy to support the widespread use of effective genomic tools, the PHG Foundation is leading an ongoing initiative in partnership with the Royal College of Physicians and Health Education England to boost clinical engagement with genomics as an essential prerequisite to widespread personalised medicine within the NHS. This includes dedicated educational resources and a leadership group of 'clinical champions'. There are over 200,000 clinicians in the UK, very few of whom are either clinical geneticists or likely to undertake the HEE Masters in Genomic Medicine - but all of whom should be aware of emerging opportunities to improve patient care in their own specialties.

Dr Hilary Burton, Director, PHG Foundation

15.15 Omics – the big debate:

There is much debate about the interplay between genomics, proteomics, pharmacogenomics and other 'omics. Discover which takes the lead and how they can be used in tandem in the quest for improved patient outcomes

The development and application of proteomics and mass spectrometry to clinical biomarker research for precision medicine.

Prof Whetton will discuss moves to industrialise the mass spectrometry approach in the new research centre in Manchester and the value of proteomics for finding new targets in disease, highlighting this from work on Chronic Myeloid Leukaemia

Professor Tony Whetton, Director of the Stoller Centre for Biomarker Discovery and also the Manchester Precision Medicine Institute. Principal investigator of the Leukaemia Lymphoma Research Mass Spectrometry programme based at the Wolfson Molecular Imaging Centre, Christie Hospital

16.15 Partnerships in Precision Medicine – The crucial need for collaboration

Dr Ruth McKernan, Chief Executive, Innovate UK

Dr Rebecca Lumsden, Head of Science Policy, ABPI

Dr Desmond Walsh, Head, Population and Systems Medicine; Lead for Stratified Medicine, Medical Research Council

17.15 Closing Remarks from The Chair

Vivienne Parry OBE

17.20 Conference Close

Check out our new website

www.precisionmedicineforum.com

Precision Medicine Forum is designed to be the go to place for unparalleled networking – and for facilitating the exchange of information, expertise and ideas – among world-leading scientific, academic and business minds. Our social media groups, blogs, webinars, newsletters and live events bring communities together in person and online. We provide the opportunity to share in the collective wisdom of your peers, discover uncharted business opportunities and deliver the right content, at the right time to the right people.



Join Our LinkedIn Group

We believe that connecting with other leading minds is the best way to grow your brand and business

Sponsorship/exhibitor opportunities

The format of Precision Medicine Forum offers a unique environment to make new connections, share ideas and formulate partnerships for future collaboration. As a sponsor we work with you to ensure that your objectives are met by building bespoke packages. These can range from exhibition stands to moderation of roundtables, sponsorship of gala dinners to playing your corporate video during a break.

- Build your brand presence
- Demonstrate your expertise and thought leadership
- Showcase your products and services
- Generate new business leads
- Align yourself with the leading organisations in the Precision Medicine arena

Don't forget, – it's not just about the conference itself. As a sponsor you'll be afforded considerable marketing exposure across a whole variety of channels before, during and post event through Precision Medicine Forum online, via our social media and affiliates.

For further information please contact us:
marketing@precisionmedicineforum.com
T: +44 (0)1273 931616

Conference Delegate fee:

Academic/Hospital: £600+VAT
Standard Delegate: £995 +VAT

Fee includes:

- Conference Pass
- Delegate Programme
- Buffet lunch, snacks and refreshments throughout the conference
- Complimentary Networking Drinks Reception

Due to demand we are now offering one day only registration. Please use the discount code "Monday" or "Tuesday" depending on the day you wish to attend. Pricing is 50% discount from the standard two rate.

Venue:

Park Plaza Victoria
239 Vauxhall Bridge Road
London SW1V 1EQ
United Kingdom

Situated just two minutes from Victoria railway station with fast links to London Gatwick Airport, and the London Underground network, bus and coach terminals, Park Plaza Victoria London hotel is easily accessible by all forms of public transport.

How to Register:

W: www.precisionmedicineforum.com/conferences

E: register@precisionmedicineforum.com

T: +44(0)1273 931616